secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001558370-25-007410
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q1 2025: LOQTORZI rev $7.3M, net loss $47.4M; UDENYCA divestiture closed
--------------------------------------------------------------------------------

- Continuing ops net loss $47.4M ($0.41 diluted); non-GAAP net loss $40.9M ($0.35).
- LOQTORZI net revenue $7.3M, patient demand grew >15% vs Q4 2024.
- UDENYCA divestiture closed April 2025 for upfront $483.4M, total up to $558.4M.
- CHS-114 Phase 1b shows confirmed partial response in PD-1 refractory HNSCC; proof of mechanism.
- Casdozokitug Phase 2 randomized trial in 1L HCC enrolling; data readout expected 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/0001558370-25-007410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer